Phase 1 trial of TSR-022 in combination with an anti-PD-1 antibody, TSR-042, in solid tumour patients

Trial Profile

Phase 1 trial of TSR-022 in combination with an anti-PD-1 antibody, TSR-042, in solid tumour patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs TSR 022 (Primary) ; TSR 042 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms AMBER
  • Most Recent Events

    • 07 Nov 2017 According to a TESARO Inc. media release, the company expects to present initial data from the combination study in 2018.
    • 07 Nov 2017 Data from the monotherapy, dose-escalation portion of this trial will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting 2017, according to a TESARO Inc. media release.
    • 09 Aug 2017 According to a TESARO media release, Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top